Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, 100191, China.
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
J Transl Med. 2017 Jul 19;15(1):159. doi: 10.1186/s12967-017-1260-2.
ETS2 is a downstream effector of the RAS/RAF/ERK pathway, which plays a critical role in the development of malignant tumor. However, the clinical impact of ETS2 expression in AML remains unknown.
In this study, we evaluated the prognostic significance of ETS2 expression using two relatively large cohorts of AML patients.
In the first cohort, compared to low expression of ETS2 (ETS2 ), high expression of ETS2 (ETS2 ) showed significant shorter OS, EFS and RFS in the current treatments including the allogeneic HCT group (n = 72) and the chemotherapy group (n = 100). Notably, among ETS2 patients, those received allogeneic HCT had longer OS, EFS and RFS than those with chemotherapy alone (allogeneic HCT, n = 39 vs. chemotherapy, n = 47), but treatment modules play insignificant role in the survival of ETS2 patients (allogeneic HCT, n = 33 vs. chemotherapy, n = 53). Moreover, gene/microRNA expression data provides insights into the biological changes associated with varying ETS2 expression levels in AML. The prognostic value of ETS2 was further validated in the second AML cohort (n = 329).
Our results indicate that ETS2 is a poor prognostic factor in AML and may guide treatment decisions towards allogeneic HCT.
ETS2 是 RAS/RAF/ERK 通路的下游效应物，在恶性肿瘤的发展中起着关键作用。然而，ETS2 表达在 AML 中的临床影响尚不清楚。
在这项研究中，我们使用两个相对较大的 AML 患者队列评估了 ETS2 表达的预后意义。
在第一个队列中，与 ETS2 低表达（ETS2 ）相比，高表达 ETS2 （ETS2 ）在当前治疗方案中，包括异基因 HCT 组（n=72）和化疗组（n=100）中，OS、EFS 和 RFS 明显更短。值得注意的是，在 ETS2 低表达的患者中，接受异基因 HCT 的患者的 OS、EFS 和 RFS 均长于单独接受化疗的患者（异基因 HCT，n=39 与化疗，n=47），但治疗方案在 ETS2 低表达患者的生存中作用不显著（异基因 HCT，n=33 与化疗，n=53）。此外，基因/miRNA 表达数据提供了有关 AML 中 ETS2 表达水平变化相关生物学变化的见解。ETS2 的预后价值在第二个 AML 队列（n=329）中得到了进一步验证。
我们的结果表明，ETS2 是 AML 的不良预后因素，可能指导异基因 HCT 治疗决策。
Zotero 插件
